keyword
https://read.qxmd.com/read/38534956/paraneoplastic-syndromes-in-neuroendocrine-prostate-cancer-a-systematic-review
#1
REVIEW
Mohammad Abufaraj, Raghad Ramadan, Amro Alkhatib
Neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming more frequent. It can initially manifest as PNS, complicating diagnosis. Therefore, we reviewed the literature on the different PNS associated with NEPC. We systematically reviewed English-language articles from January 2017 to September 2023, identifying 17 studies meeting PRISMA guidelines for NEPC and associated PNS...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38530086/combined-therapy-targeting-ar-and-ezh2-curbs-castration-resistant-prostate-cancer-enhancing-anti-tumor-t-cell-response
#2
JOURNAL ARTICLE
Irene Fischetti, Laura Botti, Roberta Sulsenti, Valeria Cancila, Claudia Enriquez, Renata Ferri, Marco Bregni, Filippo Crivelli, Claudio Tripodo, Mario P Colombo, Elena Jachetti
Aim: Castration-resistant prostate cancer (CRPC) eventually becomes resistant to androgen receptor pathway inhibitors like enzalutamide. Immunotherapy also fails in CRPC. We propose a new approach to simultaneously revert enzalutamide resistance and rewire anti-tumor immunity. Methods: We investigated in vitro and in subcutaneous and spontaneous mouse models the effects of combining enzalutamide and GSK-126, a drug inhibiting the epigenetic modulator EZH2. Results: Enzalutamide and GSK-126 synergized to reduce CRPC growth, also restraining tumor neuroendocrine differentiation...
March 26, 2024: Epigenomics
https://read.qxmd.com/read/38515575/a-systematic-review-of-primary-large-cell-neuroendocrine-carcinoma-of-the-prostate
#3
Ngan Nguyen, Ronald Dean Franz, Omar Mohammed, Richard Huynh, Christine Kim Son, Rida Nusrat Khan, Bilawal Ahmed
BACKGROUND: Large cell neuroendocrine carcinoma (LCNEC) is a rare subtype of prostate cancer. The pathogenesis, clinical manifestation, treatment options, and prognosis are uncertain and underreported. MATERIALS AND METHODS: A systematic search was conducted in April 2022 through PubMed, Embase, and Cochrane. We reviewed cases of LCNEC developed either from de novo or transformation from prostate adenocarcinoma and summarized the relevant pathophysiological course, treatment options, and outcomes...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38488813/integrative-molecular-analyses-of-the-md-anderson-prostate-cancer-patient-derived-xenograft-mda-pca-pdx-series
#4
JOURNAL ARTICLE
Nicolas Anselmino, Estefania Labanca, Peter D A Shepherd, Jiabin Dong, Jun Yang, Xiaofei Song, Subhiksha Nandakumar, Ritika Kundra, Cindy J Lee, Nikolaus Schultz, Jianhua Zhang, John C Araujo, Ana M Aparicio, Sumit K Subudhi, Paul G Corn, Louis L Pisters, John F Ward, John W Davis, Elba S Vazquez, Geraldine Gueron, Christopher J Logothetis, Andrew Futreal, Patricia Troncoso, Yu Chen, Nora M Navone
PURPOSE: Develop and deploy a robust discovery platform that encompasses heterogeneity, clinical annotation, and molecular characterization and overcomes the limited availability of prostate cancer (PCa) models. This initiative builds on the rich MD Anderson (MDA) PCa patient-derived xenograft (PDX) resource to complement existing publicly available databases by addressing gaps in clinically annotated models reflecting the heterogeneity of potentially lethal and lethal PCa. EXPERIMENTAL DESIGN: We performed whole-genome, targeted, and RNA sequencing in representative samples of the same tumor from 44 PDXs derived from 38 patients linked to donor tumor metadata and corresponding organoids...
March 15, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38485583/radiotheranostics-global-market-and-future-developments
#5
REVIEW
Akram Al-Ibraheem, Richard Zimmermann, Ahmed S Abdlkadir, Ken Herrmann
Radiotheranostics, a combination of diagnostic and therapeutic approaches, was first utilized in cancer management using radiopharmaceuticals to both image and selectively treat specific cancer subtypes nearly a century ago. Radiotheranostic strategies rooted in nuclear medicine have revolutionized the treatment landscape for individuals diagnosed with prostate cancer and neuroendocrine tumors in the past 10 years. In specific contexts, these approaches have emerged as the prevailing standard, yielding numerous positive results...
March 13, 2024: Seminars in Nuclear Medicine
https://read.qxmd.com/read/38480799/a-platform-independent-ai-tumor-lineage-and-site-atlas-classifier
#6
JOURNAL ARTICLE
Nicholas R Rydzewski, Yue Shi, Chenxuan Li, Matthew R Chrostek, Hamza Bakhtiar, Kyle T Helzer, Matthew L Bootsma, Tracy J Berg, Paul M Harari, John M Floberg, Grace C Blitzer, David Kosoff, Amy K Taylor, Marina N Sharifi, Menggang Yu, Joshua M Lang, Krishnan R Patel, Deborah E Citrin, Kaitlin E Sundling, Shuang G Zhao
Histopathologic diagnosis and classification of cancer plays a critical role in guiding treatment. Advances in next-generation sequencing have ushered in new complementary molecular frameworks. However, existing approaches do not independently assess both site-of-origin (e.g. prostate) and lineage (e.g. adenocarcinoma) and have minimal validation in metastatic disease, where classification is more difficult. Utilizing gradient-boosted machine learning, we developed ATLAS, a pair of separate AI Tumor Lineage and Site-of-origin models from RNA expression data on 8249 tumor samples...
March 13, 2024: Communications Biology
https://read.qxmd.com/read/38479871/treatment-outcomes-of-second-line-systemic-therapy-for-neuroendocrine-prostate-cancer-a-report-of-four-cases
#7
JOURNAL ARTICLE
Yuto Tsubonuma, Keita Funakoshi, Tomohisa Takaba, Kazumasa Jyojima, Akinori Minato, Ikko Tomisaki, Kenichi Harada, Naohiro Fujimoto
Neuroendocrine prostate cancer (NEPC) is a histological variant of prostate cancer and is characterized by aggressiveness and poor clinical outcomes. NEPC usually develops as a mechanism of treatment resistance in patients receiving hormone therapy for advanced prostate cancer. NEPC is sensitive to primary platinum-based chemotherapy, and has a short response duration. Second-line therapy is required in many cases, but clinical data on subsequent treatment after progression to first-line chemotherapy is limited...
2024: Journal of UOEH
https://read.qxmd.com/read/38458555/multifaced-roles-of-the-long-non-coding-rna-draic-in-cancer-progression
#8
REVIEW
Kouhei Sakurai, Hiroyasu Ito
Long non-coding RNAs (lncRNA) are functional RNAs, with over 200 nucleotides in length and lacking protein-coding potential. Studies have indicated that lncRNAs are important gene regulators under physiological conditions. Aberrant lncRNA expression is associated with the initiation and progression of various diseases, including cancers. High-throughput transcriptome analyses have revealed thousands of lncRNAs as putative tumor suppressors or promoters in various cancers, but the detailed molecular mechanisms of each lncRNA remain unclear...
March 6, 2024: Life Sciences
https://read.qxmd.com/read/38451196/positron-emission-computed-tomography-targeting-urokinase-plasminogen-activator-receptor-upar-in-cancer-a-systematic-review
#9
REVIEW
Riccardo Camedda, Viviana Frantellizzi, Roberta Danieli, Giuseppe De Vincentis, Luca Filippi
INTRODUCTION: To provide an overview of the available literature data on clinical applications of positron emission tomography (PET) targeting the urokinase-type plasminogen activator receptor in oncology. METHODS: A literature search was conducted in PubMed, Web of Science and Scopus databases up to June 2023. The results were presented according to the PRISMA guidelines. The quality of the studies was assessed using the Critical Appraisal Skill Program checklist...
March 7, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38440716/treatment-related-neuroendocrine-prostate-cancer-with-brca2-germline-mutation-treated-with-olaparib
#10
Riko Ikeda, Yoh Matsuoka, Masaharu Inoue, Ayataka Ishikawa, Kiwamu Akagi, Yukio Kageyama
INTRODUCTION: The efficacy of olaparib for treatment-related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment-related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1-year efficacy. CASE PRESENTATION: A 75-year-old man initially diagnosed with prostate adenocarcinoma developed treatment-related neuroendocrine prostate cancer after 10-year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation...
March 2024: IJU case reports
https://read.qxmd.com/read/38433714/development-of-novel-models-of-aggressive-variants-of-castration-resistant-prostate-cancer
#11
JOURNAL ARTICLE
Ludovic Bigot, Jonathan Sabio, Loic Poiraudeau, Maxime Annereau, Naoual Menssouri, Carole Helissey, Olivier Déas, Marine Aglave, Tony Ibrahim, Cédric Pobel, Catline Nobre, Claudio Nicotra, Maud Ngo-Camus, Ludovic Lacroix, Etienne Rouleau, Lambros Tselikas, Jean-Gabriel Judde, Anne Chauchereau, Alice Bernard-Tessier, Anna Patrikidou, Natacha Naoun, Ronan Flippot, Emeline Colomba, Alina Fuerea, Laurence Albiges, Pernelle Lavaud, Christophe Massard, Luc Friboulet, Karim Fizazi, Benjamin Besse, Jean-Yves Scoazec, Yohann Loriot
BACKGROUND: Genomic studies have identified new subsets of aggressive prostate cancer (PCa) with poor prognosis (eg, neuroendocrine prostate cancer [NEPC], PCa with DNA damage response [DDR] alterations, or PCa resistant to androgen receptor pathway inhibitors [ARPIs]). Development of novel therapies relies on the availability of relevant preclinical models. OBJECTIVE: To develop new preclinical models (patient-derived xenograft [PDX], PDX-derived organoid [PDXO], and patient-derived organoid [PDO]) representative of the most aggressive variants of PCa and to develop a new drug evaluation strategy...
October 26, 2023: European Urology Oncology
https://read.qxmd.com/read/38428891/brain-metastasis-in-a-patient-with-brca2-mutated-treatment-related-neuroendocrine-prostate-carcinoma-and-long-term-response-to-radiotherapy-and-olaparib-a-case-report-and-literature-review
#12
JOURNAL ARTICLE
Rio Uehara, Daisuke Obinata, Sho Hashimoto, Ken Nakahara, Hideaki Uchida, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi, Masakuni Sakaguchi, Yoshinari Ozawa, Fumi Mori, Katsuhiro Miura, Toshiyuki Ishige, Shinobu Masuda, Tomohiro Nakayama, Satoru Takahashi
BACKGROUND: A new subtype of prostate cancer called treatment-related neuroendocrine prostate carcinoma (t-NEPC) was added to the revised World Health Organization classification of prostate cancer in 2022. t-NEPC cases are increasing, and there is no established standard treatment. METHODS: A 49-year-old male patient was referred to our department for dysuria. A rectal examination and a prostate biopsy revealed stony hardness and prostate adenocarcinoma, respectively...
March 1, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38427957/18f-fdg-and-68ga-psma-pet-ct-in-paratesticular-mesothelioma
#13
JOURNAL ARTICLE
Forough Kalantari, Gregor Schweighofer-Zwink, Gundula Rendl, Christian Pirich, Mohsen Beheshti
A 66-year-old man with local prostate adenocarcinoma underwent radical prostatectomy (Gleason score 3 + 4 = 7, pT2c) in 2016. Four years later, he presented with a hydrocele and cystic atypical change in the left scrotum and soft tissue in the left groin. Final histopathology revealed spermatic cord mesothelioma and left hemangiosis carcinomatosa. A bone biopsy of the sacrum revealed infiltrates of a prostatic adenocarcinoma with small cell neuroendocrine differentiation. Dual-tracer PET/CT imaging using 18F-FDG and 68Ga-PSMA was able to identify local recurrence of scrotal mesothelioma and differentiate metastases of prostate cancer from malignant mesothelioma...
April 1, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38421515/nuclear-medicine-practice-in-japan-a-report-of-the-ninth-nationwide-survey-in-2022
#14
JOURNAL ARTICLE
Atsutaka Okizaki, Yoshihiro Nishiyama, Yoshitaka Inui, Hideki Otsuka, Kentaro Takanami, Masatoyo Nakajo, Koya Nakatani, Munenobu Nogami, Kenji Hirata, Yukito Maeda, Mana Yoshimura, Hiroshi Wakabayashi
Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. The subcommittee sent questionnaires, including the number and category of examinations as well as the kind of the radiopharmaceuticals during the 30 days of June 2022 to all nuclear medicine institutes in Japan. The total numbers of them for the year 2022 were estimated depends on the 1-month data...
February 29, 2024: Annals of Nuclear Medicine
https://read.qxmd.com/read/38409763/dual-177lu-prostate-specific-membrane-antigen-and-177lu-dotatate-therapy-in-metastatic-castration-resistant-prostate-cancer-with-neuroendocrine-differentiation
#15
JOURNAL ARTICLE
Ediz Beyhan, Özge Erol Fenercioğlu, Rahime Şahin, Tevfik Fikret Çermik, Nurhan Ergül
We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine differentiation, posttherapy results to consecutive 177Lu-prostate-specific membrane antigen and 177Lu-DOTATATE. Despite hormonal therapy and chemoradiotherapy, the patient progressed rapidly, and multiple liver and bone metastases showed regression after 177Lu-prostate-specific membrane antigen and 177Lu-DOTATATE treatment. Prostate cancer with neuroendocrine differentiation is resistant to treatments; however, treatment with the combination of 177Lu-DOTATATE therapy may be promising...
February 27, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38405800/lineage-specific-canonical-and-non-canonical-activity-of-ezh2-in-advanced-prostate-cancer-subtypes
#16
Varadha Balaji Venkadakrishnan, Adam G Presser, Richa Singh, Matthew A Booker, Nicole A Traphagen, Kenny Weng, Nathaniel C Voss, Navin R Mahadevan, Kei Mizuno, Loredana Puca, Osasenaga Idahor, Sheng-Yu Ku, Martin K Bakht, Ashir A Borah, Zachary T Herbert, Michael Y Tolstorukov, David A Barbie, David S Rickman, Myles Brown, Himisha Beltran
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration resistant prostate cancers and implicated as a driver of disease progression and resistance to hormonal therapies. Here we define the lineage-specific action and differential activity of EZH2 in both prostate adenocarcinoma (PRAD) and neuroendocrine prostate cancer (NEPC) subtypes of advanced prostate cancer to better understand the role of EZH2 in modulating differentiation, lineage plasticity, and to identify mediators of response and resistance to EZH2 inhibitor therapy...
February 8, 2024: Research Square
https://read.qxmd.com/read/38396008/single-cell-transcriptomic-analysis-informs-the-lncrna-landscape-in-metastatic-castration-resistant-prostate-cancer
#17
JOURNAL ARTICLE
Debanjan Saha, Ha X Dang, Meng Zhang, David A Quigley, Felix Y Feng, Christopher A Maher
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal form of prostate cancer. Although long-noncoding RNAs (lncRNAs) have been implicated in mCRPC, past studies have relied on bulk sequencing methods with low depth and lack of single-cell resolution. Hence, we performed a lncRNA-focused analysis of single-cell RNA-sequencing data (n = 14) from mCRPC biopsies followed by integration with bulk multi-omic datasets. This yielded 389 cell-enriched lncRNAs in prostate cancer cells and the tumor microenvironment (TME)...
February 23, 2024: NPJ Genomic Medicine
https://read.qxmd.com/read/38391963/subtype-transdifferentiation-in-human-cancer-the-power-of-tissue-plasticity-in-tumor-progression
#18
REVIEW
Monica Fedele, Laura Cerchia, Sabrina Battista
The classification of tumors into subtypes, characterized by phenotypes determined by specific differentiation pathways, aids diagnosis and directs therapy towards targeted approaches. However, with the advent and explosion of next-generation sequencing, cancer phenotypes are turning out to be far more heterogenous than initially thought, and the classification is continually being updated to include more subtypes. Tumors are indeed highly dynamic, and they can evolve and undergo various changes in their characteristics during disease progression...
February 17, 2024: Cells
https://read.qxmd.com/read/38381121/immunosuppressive-role-of-bdnf-in-therapy-induced-neuroendocrine-prostate-cancer
#19
JOURNAL ARTICLE
Yen-Nien Liu, Wei-Yu Chen, Ming-Kun Liu, Hsiu-Lien Yeh, Wei-Hao Chen, Kuo-Ching Jiang, Han-Ru Li, Zi-Qing Chen, Wan-Hsin Wang, Wassim Abou-Kheir, Yu-Ching Wen
Prostate stromal cells play a crucial role in the promotion of tumor growth and immune evasion in the tumor microenvironment (TME) through intricate molecular alterations in their interaction with prostate cancer (PCa) cells. While the impact of these cells on establishing an immunosuppressive response and influencing PCa aggressiveness remains incompletely understood. Our study shows that the activation of the leukemia inhibitory factor (LIF)/LIF receptor (LIFR) pathway in both prostate tumor and stromal cells, following androgen deprivation therapy (ADT), leads to the development of an immunosuppressive TME...
February 21, 2024: Molecular Oncology
https://read.qxmd.com/read/38379396/ferroptosis-and-ferroptosis-inducing-nanomedicine-as-a-promising-weapon-in-combination-therapy-of-prostate-cancer
#20
REVIEW
Mengjun Huang, Qiliang Teng, Fei Cao, Jinsheng Huang, Jun Pang
Incidence and mortality of prostate cancer (PCa) rank in the top five among male tumors. However, single treatment modalities are often restricted due to biochemical recurrence and drug resistance, necessitating the development of new approaches for the combination treatment of castration-resistant and neuroendocrine PCa. Ferroptosis is characterized by the accumulation of iron-overload-mediated lipid peroxidation and has shown promising outcomes in anticancer treatment, prompting us to present a review reporting the application of ferroptosis in the treatment of PCa...
February 21, 2024: Biomaterials Science
keyword
keyword
83546
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.